AIM
AIM ImmunoTech Inc.
There isn't enough reported data to score AIM yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
AIM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AIM's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AIM PE Valuation
AIM has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AIM's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.79 | +$11.85 |
| Q2 2026 | -$9.10 | +$14.84 |
| Q1 2026 | -$12.24 | +$11.04 |
| Q4 2025 | -$16.40 | +$13.67 |
| Q3 2025 | -$19.64 | +$25.95 |
| Q2 2025 | -$23.94 | +$31.35 |
| Q1 2025 | -$23.28 | +$38.80 |
| Q4 2024 | -$30.07 | +$28.13 |
AIM is still losing money, but far less than before: $7.79 per share over the past year, against $546.07 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AIM on earnings quality, reporting a profit while its opponent remains loss making.
AIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22K | -15% |
| Q2 2026 | $26K | +4% |
| Q1 2026 | $22K | +38% |
| Q4 2025 | $21K | -53% |
| Q3 2025 | $26K | -26% |
| Q2 2025 | $25K | -50% |
| Q1 2025 | $16K | -60% |
| Q4 2024 | $45K | -31% |
AIM's revenue has slid since its 2023 peak: $22,000 last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13441% | -4029 points |
| Q2 2026 | -13512% | -2928 points |
| Q1 2026 | -10118% | +12501 points |
| Q4 2025 | -14057% | -1046 points |
| Q3 2025 | -9412% | +3414 points |
| Q2 2025 | -10584% | -3196 points |
| Q1 2025 | -22619% | -8284 points |
| Q4 2024 | -13011% | +8534 points |
AIM's operating margin was −13441% last quarter, down 4029 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AIM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AIM on profitability, with a higher operating margin.
AIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.6M | -$3.1M |
| Q1 2026 | -$2.7M | -$358K |
| Q2 2025 | -$1.5M | +$1.5M |
| Q1 2025 | -$2.4M | +$2.5M |
| Q2 2024 | -$3M | -$850K |
| Q1 2024 | -$4.8M | -$1.1M |
| Q4 2021 | -$5.8M | -$2.9M |
| Q3 2021 | -$3.5M | -$472K |
AIM has burned cash in almost every quarter: −$12M over the past year, against −$14M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
AIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +90% | +15.4M shares |
| 1 year | +4051% | +31.7M shares |
| 3 years | +6411% | +32M shares |
| 5 years | +8001% | +32.1M shares |
AIM has 32M diluted shares, up 4051% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over AIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AIM Net Leverage
AIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 5.5 | Oversold |
AIM's weekly RSI is 29 (oversold) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AIM PE vs Healthcare Sector
AIM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 12% below |
| 20 week MA | $0.22 | 32% below |
| 50 week MA | $0.58 | 74% below |
| 100 week MA | $4.33 | 97% below |
| 200 week MA | $22.8 | 99% below |
AIM is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AIM on trend strength, trading above more of its moving averages.
AIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.8 | $195.0 | +284% |
| 2021 | $195.0 | $103.8 | -47% |
| 2022 | $103.8 | $34.8 | -66% |
| 2023 | $34.8 | $41.4 | +19% |
| 2024 | $41.4 | $19.8 | -52% |
| 2025 | $19.8 | $1.25 | -94% |
| 2026 YTD | $1.25 | $0.15 | -88% |
AIM's yearly returns have swung widely, from +284% in 2020 to −94% in 2025. It's down 88% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AIM on returns for 2026, with the stronger performance.